Bristol Myers Squibb (CELG-RI) Deferred Taxes (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Deferred Taxes of $161.0 million for Q1 2026, down 27.8% year-over-year from $223.0 million in Q1 2025, and up 141.07% quarter-over-quarter from -$392.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Deferred Taxes (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Deferred Taxes data on file, last reported at $161.0 million in Q1 2026.
- Deferred Taxes for Q1 2026 came in at $161.0 million, down 27.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 billion (up 11.08% YoY), and the FY2025 annual result was -$965.0 million, up 53.81% from the prior year.
- Deferred Taxes improved to $161.0 million in Q1 2026 per CELG-RI's latest filing, from -$392.0 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $223.0 million in Q1 2025 and troughed at -$1.3 billion in Q4 2023.
- A 5-year average of -$524.6 million and a median of -$548.0 million in 2023 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2022 and 2025: Deferred Taxes plunged 1915.62% in 2022, then surged 131.36% in 2025.
- A 5-year view of Deferred Taxes shows it stood at -$624.0 million in 2022, then tumbled by 112.66% to -$1.3 billion in 2023, then soared by 40.39% to -$791.0 million in 2024, then surged by 50.44% to -$392.0 million in 2025, then surged by 141.07% to $161.0 million in 2026.
- Business Quant data shows CELG-RI's Deferred Taxes at $161.0 million in Q1 2026, -$392.0 million in Q4 2025, and -$359.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 161.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 161.00 Mn |
| Dec 31, 2025 | -392.00 Mn |
| Sep 30, 2025 | -359.00 Mn |
| Jun 30, 2025 | -437.00 Mn |
| Mar 31, 2025 | 223.00 Mn |
| Dec 31, 2024 | -791.00 Mn |
| Sep 30, 2024 | -256.00 Mn |
| Jun 30, 2024 | -331.00 Mn |
| Mar 31, 2024 | -711.00 Mn |
| Dec 31, 2023 | -1.33 Bn |
| Sep 30, 2023 | -327.00 Mn |
| Jun 30, 2023 | -1.09 Bn |
| Mar 31, 2023 | -548.00 Mn |
| Dec 31, 2022 | -624.00 Mn |
| Sep 30, 2022 | -645.00 Mn |
| Jun 30, 2022 | -782.00 Mn |
| Mar 31, 2022 | -687.00 Mn |
| Dec 31, 2021 | -1.27 Bn |
| Sep 30, 2021 | -32.00 Mn |
| Jun 30, 2021 | -163.00 Mn |